http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Jeonghwan,Cho, Jang-Hee,Lee, Jong Soo,Ahn, Dong-Won,Kim, Chan-Duck,Ahn, Curie,Jung, In Mok,Han, Duck Jong,Lim, Chun Soo,Kim, Yon Su,Kim, Young Hoon,Lee, Jung Pyo Wolters Kluwer Health 2016 Medicine Vol.95 No.21
<▼1><P>Supplemental Digital Content is available in the text</P></▼1><▼2><P><B>Abstract</B></P><P>Clinical outcomes in kidney transplant recipients (KTRs) with hepatitis B virus (HBV) have not been thoroughly evaluated. Here, we investigated recent posttransplant clinical outcomes of KTRs with HBV and compared them with KTRs with hepatitis C virus (HCV) and seronegative KTRs.</P><P>Of 3855 KTRs from April 1999 to December 2011, we enrolled 3482 KTRs who had viral hepatitis serology data; the patients were followed up for 89.1 ± 54.1 months. The numbers of recipients with HBV and HCV were 160 (4.6%) and 55 (1.6%), respectively. We analyzed the clinical outcomes, including overall mortality and graft failure, among patients who had undergone kidney transplantation.</P><P>Patients with HBV showed poorer survival (<I>P</I> = 0.019; adjusted hazard ratio [HR] = 2.370; 95% confidence interval [CI]: 1.155–4.865) than KTRs without HBV. However, the graft survival of patients with chronic hepatitis B did not differ from that of patients without HBV. Hepatic complications were the primary causes of mortality of KTRs with HBV. Mortality significantly correlated with a higher grade of inflammation (<I>P</I> = 0.002) and with the use of lamivudine or adefovir antiviral treatment (<I>P</I> = 0.016). HBV-positive KTRs treated with the new-generation antiviral agent entecavir showed improved patient survival compared with KTRs receiving lamivudine (log-rank <I>P</I> = 0.050). HCV did not affect patient survival; however, it increased the incidence of graft failure (<I>P</I> = 0.010; adjusted HR = 2.899; 95% CI: 1.289–6.519). KTRs with HCV had an increased incidence of acute rejection (log-rank <I>P</I> = 0.005, crude HR = 2.144; 95% CI: 1.341–3.426; <I>P</I> = 0.001).</P><P>KTRs with chronic hepatitis B may exhibit poor survival due to post-transplantation hepatic complications. Pretransplant histological liver evaluations and adequate antiviral management with potent nucleoside/nucleotide analogues are needed to improve the survival of KTRs with chronic hepatitis B even when liver function is within the normal range.</P></▼2>
A Review of Intelligent Self-Driving Vehicle Software Research
( Jeonghwan Gwak ),( Juho Jung ),( Ryumduck Oh ),( Manbok Park ),( Mukhammad Abdu Kayumbek Rakhimov ),( Junho Ahn ) 한국인터넷정보학회 2019 KSII Transactions on Internet and Information Syst Vol.13 No.11
Interest in self-driving vehicle research has been rapidly increasing, and related research has been continuously conducted. In such a fast-paced self-driving vehicle research area, the development of advanced technology for better convenience safety, and efficiency in road and transportation systems is expected. Here, we investigate research in self-driving vehicles and analyze the main technologies of driverless car software, including: technical aspects of autonomous vehicles, traffic infrastructure and its communications, research techniques with vision recognition, deep leaning algorithms, localization methods, existing problems, and future development directions. First, we introduce intelligent self-driving car and road infrastructure algorithms such as machine learning, image processing methods, and localizations. Second, we examine the intelligent technologies used in self-driving car projects, autonomous vehicles equipped with multiple sensors, and interactions with transport infrastructure. Finally, we highlight the future direction and challenges of self-driving vehicle transportation systems.
( Jeonghwan Lee ),( Seong Woo Lee ),( Jae Wook Lee ),( Ho Jun Chin ),( Kwon Wook Joo ),( Yon Su Kim ),( Curie Ahn ),( Suhnggwon Kim ),( Jeong Yeon Cho ),( Jin Suk Han ) 대한신장학회 2012 Kidney Research and Clinical Practice Vol.31 No.3
Background: Acute renal failure (ARF) with severe loin pain and patchy renal vasoconstriction (PRV) is a syndrome presenting with sudden loin pain after anaerobic exercise. We aimed to investigate the clinical characteristics and the efficacy of diagnostic imaging studies of patients with this syndrome. Methods: We retrospectively selected 17 patients with ARF accompanied by loin or abdominal pain who showed multiple patchy wedge-shaped delayed contrast enhancements on a computerized tomography scan. Information about the clinical characteristics, including the nature of pain and combined symptoms, suspected causes, such as exercise, drug or alcohol intake, and renal hypouricemia, and the results of laboratory and imaging tests were gathered. Results: The mean age of patients with episodes of ARF accompanied by loin pain was 23.0±6.5 (range 16-35) years old. Pain was mainly located in the loin (70.6%) or abdominal area(76.5%) and continued for approximately 3.5±4.0 days. Exercise was suspected as a primary cause of disease in 12 (70.6%) patients. Maximal serum creatinine was 5.42±3.16 (1.4-12.1)mg/dL3.1±1.8 (1-7) days after the onset of pain. The peak level of serum uric acid was 9.41±2.91 (6.0-15.8) mg/dL. All of the patients recovered to near-normal renal function, and one patient showed hypouricemia after recovery. Conclusion: ARF with severe loin pain and PRV can present with loin or abdominal pain, even without a history of anaerobic exercise. Careful history taking and appropriate imaging studies are critical in the diagnosis and management of this syndrome.
Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients
Ahn Hyun Jin,Byun Ja Min,Kim Inho,Youk Jeonghwan,Koh Youngil,Shin Dong-Yeop,Hong Junshik,Yoon Sung-Soo 대한의학회 2022 Journal of Korean medical science Vol.37 No.6
Poor graft function (PGF) is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Eltrombopag has shown multilineage responses in patients with refractory severe aplastic anemia, supporting the idea that it may improve cytopenia in patients with PGF. This retrospective, single center analysis included 8 Korean patients receiving eltrombopag for PGF. Median interval between transplant and eltrombopag treatment was 73 days, and the median duration treatment was 3.5 weeks. With median maximum daily dose of 50 mg, the time to best response was 93 days. Median hemoglobin increased from 8.2 g/dL to 10.9 g/dL, platelet from 18.5 × 109 /L to 54 × 109 /L, and absolute neutrophil count from 1.25 × 109 /L to 3.32 × 109 /L. In conclusion, eltrombopag is a good option for PGF in Korean patients, even at a lower dose compared to western patients.